Local or Whole Body Hyperthermia
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, coverage stance, prior authorization requirements, and coding for local and whole-body hyperthermia therapies for BCBSRI members, covering Medicare Advantage and Commercial products.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Medicare Advantage — Medical necessity
Medicare Advantage coverage
If the medical criteria in the online authorization tool are not met, therapy is not covered.
Commercial — Local hyperthermia
Commercial products coverage
Local hyperthermia is not medically necessary when used alone or in connection with chemotherapy; if criteria are not met the therapy may be considered not medically necessary.
Whole-body hyperthermia — Not covered / Not medically necessary
Whole-body hyperthermia
Evidence is insufficient to determine the effects of whole‑body hyperthermia on health outcomes.
Local hyperthermia is not medically necessary when used alone or in connection with chemotherapy; evidence is insufficient to determine benefit when used without radiation or with chemotherapy. Whole‑body hyperthermia is not covered (Medicare Advantage) and not medically necessary for Commercial products, based on inadequate evidence to determine effects on health outcomes.
Whole‑body hyperthermia: Not covered for Medicare Advantage Plans and not medically necessary for Commercial products; the evidence is insufficient to determine effects on health outcomes.
Local hyperthermia: Considered medically necessary for Commercial products only when the stated medical criteria are met and when used in connection with radiation therapy for primary or metastatic cutaneous or subcutaneous superficial malignancies. Local hyperthermia is not medically necessary when used alone or in connection with chemotherapy; if the specified medical criteria are not met, the therapy is not covered.
Billing Codes and Status
| 77600 | Hyperthermia, externally generated; superficial (ie, heating to a depth of 4 cm or less) |
| 77605 | Hyperthermia, externally generated; deep (ie, heating to depths greater than 4 cm) |
| 77610 | Hyperthermia generated by interstitial probe(s); 5 or fewer interstitial applicators |
| 77615 | Hyperthermia generated by interstitial probe(s); more than 5 interstitial applicators |
| 77620 | Hyperthermia generated by intracavitary probe(s) |
| Unlisted | No specific CPT procedure code for whole-body hyperthermia; report using an unlisted code |
Prior Authorization, Documentation, and Denials
Prior authorization required for Medicare Advantage
Prior authorization must be obtained for Medicare Advantage members before providing local hyperthermia; coverage is contingent on meeting the medical criteria in the online authorization tool.
- Medicare Advantage: prior authorization required
- Local hyperthermia is considered medically necessary only when online authorization criteria are met
Provider must follow authorization guidance for plan type
Follow the online authorization criteria for Medicare Advantage; for Commercial products, prior authorization is recommended and benefits may vary by contract.
- Medicare Advantage: follow online tool criteria and authorization process
- Commercial: authorization recommended; check contract-specific benefits
Documentation and benefit verification
Document prior authorization status and verify member benefits — prior authorization is required for Medicare Advantage and recommended for Commercial; benefit coverage can differ across groups/contracts so review the Benefit Booklet or Evidence of Coverage.
- Record authorization decision and link to clinical criteria from the online tool
- Check the applicable Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for radiation therapy benefits
Denial triggers — unmet criteria and whole‑body exclusion
Therapy may be denied if the medical criteria in the online authorization tool are not met; whole‑body hyperthermia is not covered for Medicare Advantage and is not medically necessary for Commercial products.
- If online authorization criteria are unmet for Medicare Advantage, local hyperthermia is not covered and may be denied
- Whole‑body hyperthermia: not covered for Medicare Advantage and not medically necessary for Commercial products
Clinical Background
Hyperthermia is a cancer treatment that exposes tissue to elevated temperatures (up to 113°F) to damage and kill cancer cells. Local hyperthermia raises the temperature of superficial or subcutaneous tumors using external or interstitial modalities while sparing surrounding normal tissue; superficial techniques typically heat to a depth of 4 cm or less and local therapy may be used in combination with radiation for primary or metastatic cutaneous or subcutaneous superficial tumors. Whole‑body hyperthermia involves raising core body temperature (described to 108°F) under general anesthesia or deep sedation, maintaining the elevated temperature for approximately 4 hours, followed by a cooling period and extended observation; this modality is considered not medically necessary.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.